The NLRP3 inflammasome was constitutively activated in COVID-19 patients with underlying liver diseases such as cirrhosis, acute live failure and non-alcoholic fatty liver disease (NAFLD) (125). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.